1. Home
  2. RDI vs QTTB Comparison

RDI vs QTTB Comparison

Compare RDI & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

HOLD

Current Price

$1.04

Market Cap

25.2M

ML Signal

HOLD

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

HOLD

Current Price

$3.01

Market Cap

25.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
QTTB
Founded
1937
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.2M
25.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RDI
QTTB
Price
$1.04
$3.01
Analyst Decision
Hold
Analyst Count
0
4
Target Price
N/A
$7.33
AVG Volume (30 Days)
469.8K
9.0M
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$211,292,000.00
N/A
Revenue This Year
$1.06
N/A
Revenue Next Year
$10.97
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.11
N/A
52 Week Low
$1.02
$1.35
52 Week High
$1.87
$6.37

Technical Indicators

Market Signals
Indicator
RDI
QTTB
Relative Strength Index (RSI) 24.54 52.61
Support Level $1.08 $2.83
Resistance Level $1.27 $3.96
Average True Range (ATR) 0.07 0.39
MACD -0.01 -0.04
Stochastic Oscillator 6.45 23.39

Price Performance

Historical Comparison
RDI
QTTB

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

Share on Social Networks: